Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLORIA: Adagloxad simolenin (OBI-822)/OBI-821 in High-Risk Early-Stage Globo H-Positive Triple Negative Breast Cancer
2023-508755-39-00Phase 3Completed
- Sponsor
- OBI Pharma
- Start
- Aug 2024
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial in triple-negative breast cancer (TNBC) comparing Adagloxad simolenin plus standard-of-care with Standard-of-care alone (2 arms). Primary endpoint: Invasive disease-free survival (IDFS). Started Aug 2024; status: completed.
02
Drugs
adagloxad simolenin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2023-508755-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508755-39-00.